Cipla prices Remdesivir at Rs 4000; Harvard, MIT sue Trump administration : News Reel: Business Today
Business Today
Loading...
 

Cipla prices Remdesivir at Rs 4000; Harvard, MIT sue Trump administration

BusinessToday.In | July 9, 2020

Cipla Ltd has priced its generic version of remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, the Indian drugmaker said on Wednesday, making it among the lowest-priced versions of the COVID-19 treatment available so far globally; Harvard University and the Massachusetts Institute of Technology (MIT) have sued the Trump administration over its decision to revoke visas of foreign students taking online-only courses in the US this fall semester; Watch this and more news on News Blast.

Also Read: Dishwasher sales grow 250%; washing machines, microwaves, refrigerators demand double



    More from this section
    11:16
    5G network will lead to endless possibilities: TRAI Chief
    02:35
    India's oil imports reach 3-year high; Biden's speech to be about unity
    04:06
    Next steps for economy and how govt can deal with resistance to reforms
    09:02
    We will see more people migrating to Signal from WhatsApp: Aruna Harder
    16:46
    Experts discuss ways by which govt could spur growth of the economy
    03:13
    Turnout dips on day 3 of vaccination; Jobs in Japan for Indians
    10:39
    Covid cess or tax deduction? What Budget 2021 has in store for taxpayers
    04:07
    There has been a shift from quantity to quality education: Rajiv Kumar
    03:03
    Wipro completes share buyback; Parl panel summons FB, Twitter
    03:03
    Farmers firm on tractor rally, get ready for 10th round of talks
    29:10
    India's first vaccine shot administered to sanitation worker at AIIMS
    02:40
    MacBook Pro 2021 to feature MagSafe, M1 chips; Shaw chosen as USIBC Vice Chair
    05:09
    DFI Blueprint for financing infrastructure
    02:29
    Biden announces $1.9 trillion stimulus; Passenger vehicle sales surge in Dec
    02:41
    Countdown begins for COVID vaccination , PM to inaugurate
    02:47
    PC sales surge in 2020; Trump impeached over US Capitol siege
    04:48
    Major risks that can disrupt the stock rally, bring down the market
    07:40
    When will the market rally hit the 1 lakh mark?
    03:04
    Tesla sets up company in Bengaluru; Trump denies responsibility for Capitol siege
    14:42
    First consignment of Covishield reaches Delhi, Chennai, Ahmedabad
    02:47
    COVID herd immunity unlikely in 2021, says WHO; Bird flu hits 10 states
    03:53
    Signal is most downloaded app as users ditch WhatsApp
    02:57
    China recovering fast, says IMF; TCS biggest gainer on Dalal Street
    04:52
    India well prepared for vaccine rollout: Dr Swaminathan
    05:09
    70% need anti-bodies to stop the virus: WHO's Swaminathan
    05:34
    12 months before full vaccine approval: WHO's Chief Scientist
    02:22
    Twitter suspends Trump's account; Brazilian Prez asks for vaccines
    02:01
    Woman fraudulently uses Ratan Tata's car number
    03:53
    Sunil Mittal on how the push-button phone began his romance with telecom
    03:53
    Bharat Biotech seeks approval from DCGI for nasal vaccine trials
    03:21
    Musk becomes world's richest person; Premji thanks Wipro employees
    03:13
    Indian Air Force to supply vaccines to remote areas
    02:11
    Who will get the COVID vaccine first? Dr Randeep Guleria answers
    03:00
    China blocks the WHO team; Pichai condemns attack at US Capitol
    21:06
    World shocked as Trump supporters storm US Capitol; 4 die, many injured
    04:39
    Snowfall in J&K, highways blocked as cold wave grips north India
    02:04
    Efficacy can be low but safety should not be compromised: Bharat Biotech chief
    02:39
    Bharat Biotech chief Dr Ella on vaccine efficacy controversy
    06:47
    Bird flu scare grips India amid the ongoing coronavirus situation
    02:48
    First vaccine shot likely on Jan 13; Ella on COVID vaccine for children